Loading...
01/11 03:26
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents mixed signals. Financial performance guidance shows modest growth, but there's a decline in gold subscriptions and uncertainty in consumer behavior. The Q&A reveals management's vague responses, which could concern investors. However, new product launches and strategic initiatives, like leveraging a large consumer base and cost controls, provide optimism. The market cap suggests moderate volatility, leading to a neutral prediction for stock price movement.
Total Revenue $203.1 million, up 1% year-over-year. The growth was in line with expectations when excluding the impact of Rite Aid bankruptcy and ISP program erosion.
Prescription Transaction Revenue Declined 3% year-over-year. The decline was attributed to the Rite Aid bankruptcy and the erosion of the ISP program.
Pharma Manufacturer Solutions Revenue $35 million, up 32% year-over-year. The increase was driven by strong performance in monetization per brand and the adoption of direct-to-patient strategies by pharma manufacturers.
Adjusted EBITDA $69.4 million, up 6% year-over-year. This improvement was due to cost reduction actions and alignment of resources to strategic priorities, resulting in a 34.2% adjusted EBITDA margin, an improvement of 160 basis points.
Cash on Hand $281.3 million at the end of the quarter. Approximately $46.4 million was used to repurchase 10.2 million shares of stock, reflecting a focus on returning excess cash to shareholders.
Condition Subscription Product for Erectile Dysfunction: Launched a subscription product for erectile dysfunction, bundling clinician visit, prescription, and delivery into one low-cost offering. Plans to expand into weight loss management and hair loss by year-end.
Prescription Savings Subscription Offering: Introduced a new prescription savings subscription sold at the pharmacy counter, with the first retail partner live in Q2.
Pharma Manufacturer Solutions Growth: Achieved 32% year-over-year revenue growth in pharma manufacturer solutions, driven by direct-to-patient strategies and consumer direct pricing models.
Pharmacy Counter Integrations: Expanded partnerships with multiple new pharmacy partners, integrating discounted pricing at the pharmacy counter.
E-commerce Solutions: Launched e-commerce solutions with an additional retailer and in contract discussions with several more.
GoodRx Community Link: Introduced a new offering for independent pharmacies, providing predictable pricing and favorable economics through a cost-plus model.
Cost Reduction and Efficiency: Took actions to reduce costs and align resources to strategic priorities, contributing to a 6% increase in adjusted EBITDA to $69.4 million.
Adjusted EBITDA Margin: Improved adjusted EBITDA margin to 34.2%, up 160 basis points year-over-year.
Leadership Changes: Appointed Laura Jensen as Chief Commercial Officer and President of Pharma Solutions, succeeding Dorothy Gemmell.
Government Engagement: Actively advocating for policies to expand access to affordable medication, positioning GoodRx as a solution for direct-to-consumer brand drug pricing.
Rite Aid bankruptcy: The bankruptcy of Rite Aid and the subsequent removal of Rite Aid from PBM networks caused an immediate cessation in associated claims volume. This was followed by the closure of over 800 stores, leading to disruptions in consumer access and challenges in recapturing displaced consumers.
Decline in integrated savings program (ISP) volume: A material decline in volume at one of the PBM partners due to restructuring of their ISP program created volume headwinds. This decline impacted the company's revenue and highlighted the dependency on PBM partners for program implementation.
Medicaid funding cuts and eligibility tightening: Recent legislation cuts funding for Medicaid and individual exchange products, tightening eligibility requirements and increasing the frequency of Medicaid coverage determinations. This could leave nearly 10 million people uninsured, potentially reducing the customer base for affordable medication solutions.
Higher-than-anticipated medical utilization: Health plans reported higher-than-expected medical utilization in 2025, suggesting rising costs, increasing premiums, and reduced coverage. This trend could impact consumer affordability and access to medications.
Government exploration of drug pricing models: Government entities are exploring models to reduce brand drug pricing directly to consumers. While this could align with GoodRx's offerings, it also introduces regulatory uncertainty and potential competitive pressures.
Dependence on pharmacy partnerships: The company's reliance on pharmacy counter integrations and e-commerce solutions to deepen partnerships poses risks if these partnerships do not materialize or fail to deliver expected results.
Economic pressures on independent pharmacies: Independent pharmacies face complex reimbursement models and competitive pressures, which could impact the adoption and success of GoodRx's Community Link program.
Revenue Growth: Pharma manufacturer solutions are projected to grow 30% or higher in 2025, driven by strong performance and increased monetization per brand.
Adjusted EBITDA: Full-year adjusted EBITDA is expected to be in the range of $265 million to $275 million, representing approximately 2% to 6% growth compared to 2024.
Revenue Impact from External Factors: The Rite Aid bankruptcy and erosion of one ISP program are expected to result in a $35 million to $40 million revenue loss in 2025.
Pharma Manufacturer Solutions: Continued focus on expanding integrated access and affordability solutions with pharma, partnering with more brands, and delivering meaningful ROI for pharma partners.
Prescription Marketplace: Efforts to deepen pharmacy relationships and expand e-commerce solutions are expected to drive long-term growth.
Subscription Services: Expansion into additional conditions such as weight loss management and hair loss is planned before the end of the year.
Healthcare Landscape Trends: Rising costs, increasing premiums, and reduced coverage are expected to continue into 2026 and beyond, creating opportunities for GoodRx to provide affordable medication solutions.
Share Repurchase Program: During the quarter, we deployed approximately $46.4 million to repurchase 10.2 million shares of our stock at an average price of $4.53 per share. At the end of the second quarter, approximately $143 million of capacity remained under our $450 million share repurchase program.
The earnings call summary and Q&A indicate strong growth prospects, particularly in manufacturer solutions and strategic initiatives, despite some headwinds like Rite Aid bankruptcy. The positive sentiment is reinforced by management's optimistic guidance and strategic focus on market expansion and partnerships. The market cap suggests a moderate reaction, leading to a 'Positive' prediction for stock price movement.
The earnings call presents mixed signals. Financial performance guidance shows modest growth, but there's a decline in gold subscriptions and uncertainty in consumer behavior. The Q&A reveals management's vague responses, which could concern investors. However, new product launches and strategic initiatives, like leveraging a large consumer base and cost controls, provide optimism. The market cap suggests moderate volatility, leading to a neutral prediction for stock price movement.
The earnings call highlighted strong financial performance, including a 217% increase in prescription transaction revenue and a positive adjusted EBITDA margin. Despite potential risks like Rite Aid's bankruptcy, the impact is expected to be minimal. The share repurchase program and positive guidance on pharma solutions growth further boost sentiment. However, some concerns about pricing pressures and competition were noted. Given the company's market cap, these factors collectively suggest a positive stock price movement of 2% to 8% over the next two weeks.
The earnings call summary shows solid financial performance with a 3% revenue increase and 11% EBITDA growth. The share repurchase program is a positive shareholder return strategy, and the Q&A revealed ongoing strategic partnerships and growth initiatives. Although guidance is cautious, the market strategy, including expanding partnerships and engaging healthcare professionals, is promising. The market cap of $2.8 billion suggests moderate volatility, supporting a positive prediction for stock movement.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
